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The 22q11.2 deletion syndrome is caused by a microdeletion of chromosome 22. One third of all patients with
22q11.2 deletion develop schizophrenia-like symptoms. In general, the prevalence of 22q11.2 deletion in patients
with schizophrenia is 1%–2%. The 22q11.2 deletion is one of the major known genetic risk factors for schizophrenia.
However, clinical differences in the phenotypes between patients with schizophrenia who are 22q11.2 deletion
carriers and those who are not are still unknown. Therefore, it may be difficult to diagnose 22q11.2 deletion in
patients with schizophrenia on the basis of clinical symptoms. To date, only two Japanese patients with the
deletion have been identified through microdeletion studies of patients with schizophrenia in the Japanese
population. Herein, we report the case study of a 48-year-old Japanese woman with 22q11.2 deletion who had a
30-year history of schizophrenia. Based on craniofacial anomalies, unpredictable agitation, hypocalcemia, and brain
imaging finding, we suspected the 22q11.2 deletion in clinical populations and diagnosed the deletion using
fluorescence in situ hybridization analysis. To find common phenotypes in Japanese patients with the deletion who
have schizophrenia-like symptoms, we compared phenotypes among three Japanese cases. The common
phenotypes were an absence of congenital cardiovascular anomalies and the presence of current findings of low
intellectual ability, agitation, and hypocalcemia. We propose that hypocalcemia and agitation in patients with
schizophrenia may derive from the 22q11.2 deletion, particularly when these phenotypes are coupled with
schizophrenia-like symptoms.
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The 22q11.2 deletion syndrome (Online Mendelian In-
heritance in Man (OMIM) 611867, also known as the
Velocardiofacial syndrome, OMIM 192430, or DiGeorge
syndrome, OMIM 188400) is caused by a microdeletion
(1.5–3 Mb) of chromosome 22, with an estimated preva-
lence of 1 in 4,500 live births [1]. The region of the
microdeletion includes approximately 35–60 known
genes, and most of the genes affected are expressed in
the brain [1]. This disorder is mainly found to have a
sporadic occurrence. The phenotypic spectrum of this
disorder is highly variable, and patients present at any* Correspondence: hashimor@psy.med.osaka-u.ac.jp
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reproduction in any medium, provided the orage. The phenotypes include congenital cardiovascular
anomalies (74% of patients), craniofacial anomalies (the
majority of patients), palatal anomalies (69%), immuno-
deficiency (77%), developmental delay or learning dis-
abilities (70%–90%), and hypocalcemia (50%) [2]. The
22q11.2 deletion is usually suspected and then diagnosed
in patients who are treated for congenital cardiovascular
anomalies coupled with other phenotypes through late
adolescence and early adulthood. Alternatively, schizo-
phrenia (OMIM 181500) is a common and complex
psychiatric disease with strong genetic components with
an estimated heritability of approximately 80% [3,4].
Schizophrenia is characterized by positive symptoms,
such as delusions and hallucinations, negative symp-
toms, such as social withdrawal and blunted affect, and
cognitive impairments. In late adolescence and early
adulthood, one third of all patients with 22q11.2 deletion
develop schizophrenia-like symptoms [5]. In general, the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phrenia is 1%–2% [6]; 22q11.2 deletion is therefore one
of the major known genetic risk factors for schizophre-
nia. To the best of our knowledge, three studies have in-
vestigated the prevalence of 22q11.2 deletion in Japanese
patients with schizophrenia [7-9]. The reported preva-
lence rates, namely 1/268 (0.37%) [7], 1/300 (0.33%) [8],
and 0/575 (0%) [9], in the Japanese population are lower
than those in other populations [6]. Thus, the 22q11.2
deletion syndrome in the clinical population of patients
with schizophrenia has been diagnosed through research
methods, such as deletion studies, but not by the clinical
symptoms observed. Therefore, it may be less likely for
clinicians to suspect and diagnose the 22q11.2 deletion
syndrome in schizophrenia patients based on clinical
symptoms alone. In this paper, we report the case study
of a Japanese woman with 22q11.2 deletion and a
30-year schizophrenia diagnosis. Based on craniofacial
anomalies, hypocalcemia, brain imaging finding, and
psychiatric symptoms such as agitation, we suggest that
the 22q11.2 deletion syndrome may be suspected and
diagnosed in patients.Figure 1 Features of a 48-year-old woman with the 22q11.2 deletion.
facial features, including a low anterior hairline, swollen eyelids, malar flatn
and flat nasal root, small mouth, and a thin upper lip. (c) Basal ganglia calc
red and green regions were detected by TUPLE1 (22q11.2) and ARSA (22q1
red and green regions, respectively. One chromosome 22 with the deletionCase presentation
The patient was a 48-year-old Japanese woman who
was diagnosed 30 years previously with schizophrenia
according to the criteria of the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV,
previously used the Third Edition). She was delivered with
forceps due to maternal fatigue (birth weight 2,500 g). Her
mother had pregnancy-induced hypertension during her
pregnancy. No cardiovascular abnormalities had been
detected at any routine medical examinations. She had no
history of feeding problems, such as regurgitation, nor did
she have symptoms of hypocalcemia in early infancy. Her
neuromotor development was slightly delayed, with par-
ticular delays in the emergence of language. She was a
slow learner and finished regular junior high school with
the lowest levels of achievement. Since childhood, she was
disposed to catching colds, suggesting immunodeficiency
resulting from thymic hypoplasia. She had a large cleft
palate causing a hypernasal voice and underwent surgery
for the cleft palate at 10 years of age (Figure 1a). Her par-
ents and three siblings were alive and well, and no other
family members or relatives are clinically affected. Since(a) Past history of an operation for cleft palate. (b) Mild dysmorphic
ess, nose with a bulbous nasal tip, hypoplastic nasal alae and a square
ification due to hypocalcemia. (d) Fluorescence in situ hybridization;
3.3) probes, respectively. The arrow and arrowhead indicate expected
of TUPLE1 (22q11.2) was detected.
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irritated and emotionally labile. At the age of 18, she
suffered from auditory hallucinations. Her family was
troubled by the unpredictable agitation and behavioral
changes associated with the hallucinations and delusions.
At the age of 22, she began going to a psychiatric hospital
regularly due to her agitation and behavioral changes.
She was diagnosed with schizophrenia, and antipsychotic
medication was initiated. For transient symptoms associ-
ated with hallucinations, delusions, insomnia, and agita-
tion, she was admitted to the hospital at the age of 30. She
had been hospitalized for a long time at Yamato Mental-
Medical Center. Although she had no history of epilepsy,
she experienced a generalized spasm when she had a lum-
bar vertebral fracture at age 46. At the time of this report,
she was 48 years old and was being treated with antipsy-
chotics (risperidone 12 mg/day), with a relatively good
control of psychotic symptoms. However, she had persist-
ent irritability, emotional lability, and unpredictable agita-
tion. She underwent surgeries for Basedow disease at 17
years old and for uterine corpus cancer at age 38.
The patient's height was 153 cm, and her weight was
63.5 kg. She had the following typical features of craniofa-
cial anomalies: a low anterior hairline, swollen eyelids,
malar flatness, a nose with a bulbous nasal tip, hypoplastic
nasal alae and a square and flat nasal root, a small mouth,
and a thin upper lip (Figure 1b), as previously reported
[10]. Her voice was hypernasal, and she had cavities due
to enamel hypoplasia. No abnormality was found on
neurological examination. Laboratory examinations re-
vealed hypocalcemia (8.1 mg/dl in serum, normal range
8.7–10.3 mg/dl, serum albumin-corrected calcium level
8.3 mg/dl) and thrombocytopenia (7.2×104 μl−1, normalTable 1 Common phenotypes of the 22q11.2 deletion syndro
presentation
Sugama et al. (in 1999
41-year-old woman
Age at onset of psychosis 22
Hallucinations and delusions +
Agitation +
Developmental delay or learning disabilities +
Low current IQ (<70) 63
Congenital cardiovascular anomalies −
Craniofacial anomalies +
Palatal anomalies −




Basal ganglia calcification +
Immunodeficiency −
Common phenotypes are shown in italics. NA not available.range 13–35×104 μl−1). Her intact parathyroid hormone
(PTH) level was within normal limits but slightly low (27
pg/ml, normal range 10–65 pg/ml), indicating that the se-
cretion of PTH from the parathyroid was not adequate
despite her hypocalcemia. The spectrum of immunodefi-
ciency ranges from absent T cells due to thymic aplasia to
normal T cell numbers [11]. In this case, the numbers of
CD4+ and CD8+ T lymphocytes were within normal
ranges. Brain CT showed bilateral basal ganglia calcifica-
tion (Figure 1c), which suggests deposition of calcium
related to hypocalcemia. Her premorbid intelligence quo-
tient (IQ), assessed by the Japanese Adult Reading Test
[12], was 80. To assess current intellectual ability, we used
a full-scale IQ of the Japanese version of the Wechsler
Adult Intelligence Scale, third edition (WAIS-III) [13].
The WAIS-III did not yield a full-scale IQ (<50; unmeas-
urable), suggesting that she showed cognitive deterior-
ation. No evidence of cardiovascular disease was found on
radiography or electrocardiograph.
The karyotype of this patient was normal (46,XX
by G-banding). Fluorescence in situ hybridization
analysis with the commercially available TUPLE1
(22q11.2) or ARSA (22q13.3) probes indicated that
the patient was hemizygous for the TUPLE1 probe
(represented by the red region in Figure 1d) and was
homozygous for the ARSA probe, represented by
the green region. According to the findings, we
diagnosed the patient as having 22q11.2 deletion
syndrome.
Discussion
We diagnosed a schizophrenia patient as having 22q11.2
deletion syndrome based on clinical symptoms. To theme in Japanese patients with a schizophrenia-like
) [7] Arinami et al. (in 2001) [8] Ohi et al. (present)















Ohi et al. Annals of General Psychiatry 2013, 12:29 Page 4 of 5
http://www.annals-general-psychiatry.com/content/12/1/29best of our knowledge, this is the first case in the
Japanese population of a patient with schizophrenia-like
psychosis to be diagnosed with 22q11.2 deletion syn-
drome based on clinical symptoms rather than micro-
deletion studies. The patient presented several typical
phenotypes of the 22q11.2 deletion. The disorder is
often suspected in the presence of congenital cardiovas-
cular anomalies coupled with other phenotypes in early
life. Although her clinical data, such as craniofacial
anomalies and cleft palate, were similar to those previ-
ously reported in 22q11.2 deletion [2], clinicians could
not diagnose her to be with 22q11.2 deletion syndrome
based on these phenotypes.
It has been reported that there are no clinical differ-
ences in the core phenotype between individuals with
schizophrenia who are 22q11.2 deletion carriers and
those who are not carriers [14,15]. Psychiatric symp-
toms and the psychiatric course in patients with the de-
letion are unremarkable. However, aggression and
temper outbursts have been commonly observed in
Caucasian patients with the 22q11.2 deletion and
schizophrenia-like symptoms [14]. To date, three cases
including the present case, which confirmed a diagnosis
of the 22q11.2 deletion syndrome following a diagnosis
of schizophrenia, have been reported in the Japanese
population. Common phenotypes in these cases were an
absence of congenital cardiovascular abnormalities and
the presence of low intellectual ability (IQ<70), agita-
tion, and hypocalcemia (Table 1). Clinical features
prompting a clinician to diagnose a patient with
22q11.2 deletion syndrome vary depending on the age
of the patient. Without such classic findings as congeni-
tal cardiovascular anomalies, clinicians may miss im-
portant diagnostic clues for 22q11.2 deletion in early
life. Identification of the 22q11 deletion syndrome, es-
pecially in adolescents and adults, may require more
careful assessments of their phenotypes apart from con-
genital cardiovascular anomalies. Current intellectual
disabilities are also common in these cases. However, a
low IQ is a well-known phenotype in patients with
schizophrenia, indicating that it is difficult to distin-
guish patients with schizophrenia from those with
22q11.2 deletion syndrome on the basis of low IQ.
Alternatively, both agitation and hypocalcemia may
prompt clinical suspicion and diagnosis of 22q11.2 dele-
tion syndrome in patients with schizophrenia. In the
present case, the patient experienced a seizure when she
had a lumbar vertebral fracture, which may have
resulted in worsening hypocalcemia due to physical
stress. In addition, agitation, irritability, and emotional
lability in these cases may derive from hypocalcemia.
We suggest that an assessment of serum calcium should
be added to the routine examination of patients with
schizophrenia.Conclusions
In this study, 22q11.2 deletion was identified in a 48-year-
old woman with schizophrenia-like symptoms as well as
hypocalcemia and agitation but without congenital heart
malformations. Notably, the absence of congenital cardio-
vascular anomalies may reduce the probability of identify-
ing 22q11.2 deletion in adult patients with schizophrenia.
We suggest that the assessment of serum calcium and agi-
tation, in addition to identification of typical craniofacial
anomalies, could aid in the diagnosis of 22q11.2 deletion
in adolescent and adult schizophrenia patients. Guidelines
for clinicians on diagnosing 22q11.2 deletion in schizo-
phrenia patients are needed.
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